Malbrán Alejandro, Juri María Cecilia, Brunzini Ricardo, Devoto Martín, Georgiett Daniel, Larrauri Blas, Torre María Gabriela, Malbrán Eloisa
Unidad de Alergia, Asma e Inmunología Clínica, Buenos Aires, Argentina.E-mail:
Unidad de Alergia, Asma e Inmunología Clínica, Buenos Aires, Argentina.
Medicina (B Aires). 2019;79(4):299-302.
Cicatrizing conjunctivitis is the final consequence of several diseases. The most severe among them are cicatricial pemphigoid and chronic Stevens-Johnson syndrome. Systemic immunosuppressive drugs and steroids are usually an effective approach to these diseases. However, a few patients follow a recalcitrant course unremitting to usual therapy. We describe the treatment with rituximab of seven patients with cicatricial pemphigoid and two with chronic Stevens-Johnson syndrome. Eight of them also received gammaglobulin and all achieved clinical remission. Three relapsed and required two or three new courses of rituximab with good control of disease activity. Rituximab proved to be an efficacious drug for chronic recalcitrant cicatrizing conjunctivitis.
瘢痕性结膜炎是多种疾病的最终结果。其中最严重的是瘢痕性类天疱疮和慢性史蒂文斯-约翰逊综合征。全身免疫抑制药物和类固醇通常是治疗这些疾病的有效方法。然而，少数患者对常规治疗反应顽固。我们描述了用利妥昔单抗治疗7例瘢痕性类天疱疮患者和2例慢性史蒂文斯-约翰逊综合征患者的情况。其中8例患者还接受了丙种球蛋白治疗，所有患者均实现临床缓解。3例复发，需要两到三个新的利妥昔单抗疗程，疾病活动得到良好控制。利妥昔单抗被证明是治疗慢性顽固性瘢痕性结膜炎的有效药物。
